Alyeska Investment Group
ATXS

Alyeska Investment Group’s Astria Therapeutics ATXS Stock Holding History

Alyeska Investment Group’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-274,719
Closed -$2.48M – 419
2022
Q3 		$2.48M Hold
274,719
– – 0.03% 309
2022
Q2 		$824K Hold
274,719
– – 0.01% 507
2022
Q1 		$1.84M Hold
274,719
– – 0.02% 442
2021
Q4 		$1.48M Buy
274,719
+50,000
+22% +$329K 0.02% 476
2021
Q3 		$1.99M Buy
224,719
+16,666
+8% +$160K 0.02% 499
2021
Q2 		$2.63M Buy
208,053
+86,169
+71% +$1.12M 0.03% 464
2021
Q1 		$2.11M Buy
+121,884
New +$2.2M 0.03% 461
2020
Q2 		– Sell
-1,007
Closed -$35.9K – 475
2020
Q1 		$25K Sell
1,007
-19,906
-95% -$617K ﹤0.01% 361
2019
Q4 		$742K Buy
+20,913
New +$659K 0.01% 335
2018
Q3 		– Sell
-18,692
Closed -$840K – 407
2018
Q2 		$1.08M Buy
18,692
+16,732
+854% +$1.54M 0.01% 392
2018
Q1 		$213K Sell
1,960
-1,685
-46% -$168K ﹤0.01% 434
2017
Q4 		$326K Hold
3,645
– – ﹤0.01% 415
2017
Q3 		$464K Buy
3,645
+65
+2% +$5.42K ﹤0.01% 442
2017
Q2 		$303K Sell
3,580
-108
-3% -$8.99K ﹤0.01% 439
2017
Q1 		$354K Sell
3,688
-43
-1% -$5.92K ﹤0.01% 459
2016
Q4 		$808K Buy
3,731
+444
+14% +$109K 0.01% 431
2016
Q3 		$1.22M Buy
+3,287
New +$866K 0.01% 406
2015
Q4 		– Sell
-670
Closed -$325K – 379
2015
Q3 		$325K Sell
670
-163
-20% -$116K ﹤0.01% 438
2015
Q2 		$611K Buy
+833
New +$630K 0.01% 443

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alyeska Investment Group's ATXS Position: Q4 2022 in Review

Alyeska Investment Group sold out of Astria Therapeutics (ATXS) in Q4 2022, closing a stake of 274,719 shares — an estimated $2.48M sold.

Alyeska Investment Group first reported a position in ATXS in Q2 2015 and held it in 19 quarters. The position peaked at $2.63M in Q2 2021. 61 funds tracked by Wall St. Rank hold ATXS as of Q4 2022.

  • Alyeska Investment Group reported no remaining Astria Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 274,719 Astria Therapeutics shares in Q4 2022, an estimated $2.48M.
  • Alyeska Investment Group first reported a position in Astria Therapeutics in Q2 2015 and held it in 19 quarters.
  • Alyeska Investment Group's Astria Therapeutics position peaked at $2.63M in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2022.

Based on Alyeska Investment Group's 13F filing for Q4 2022, filed 14 Feb 2023.